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regenerative nodules surrounded by ﬁbrous bands in response
to chronic liver injury [1]. Cirrhosis is often asymptomatic and
unsuspected until complications such as liver failure, portal
hypertension, and hepatocellular carcinoma occur. For instance,
in patients with compensated viral cirrhosis, the leading form
worldwide, the annual incidence rates of decompensation, hepa-
tocellular carcinoma, and death are approximately 4%, 3%, and 3%,
respectively [2]. Thus, early diagnosis of cirrhosis is important for
patients with chronic liver disease, because it both triggers
screening for hepatocellular carcinoma and esophageal varices,
and enables initiation of speciﬁc measures or treatment to pre-
vent disease progression, such as alcohol abstinence; antiviral
therapy for viral hepatitis; lifestyle changes in NASH; steroid
therapy for auto-immune hepatitis; and phlebotomy for
hemochromatosis.
Histological examination of a liver specimen obtained by
biopsy has traditionally been considered the reference method
for diagnosing cirrhosis [3]. Liver biopsy may also be important
for establishing the cause of cirrhosis in up to 20% of patients
with an unknown etiology [1]. However, its diagnostic accuracy
has been questioned, owing to sampling errors and intra- and
inter-observer variability, that may lead to an underestimation
of cirrhosis [4]. In addition, biopsy is an invasive and painful pro-
cedure associated with rare but potentially life-threatening com-
plications. Several non-invasive approaches have therefore been
developed, including serum biomarkers and imaging techniques
such as ultrasonography and, more recently, liver stiffness mea-
surement (LSM) by means of transient elastography (TE). Ultraso-
nography is usually the ﬁrst imaging technique to be used in the
clinical workup of patients with suspected liver diseases, as it isJournal of Hepatology 20
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left lobe liver surface; HVPG, hepatic venous pressure gradient.simple, non-invasive, inexpensive, and widely available. Features
such as caudate lobe hypertrophy and nodularity of the liver sur-
face are suggestive of cirrhosis. However, although their speciﬁc-
ity is high (91% and 95%, respectively), their sensitivity is not
good enough (41% and 54%, respectively) to diagnose cirrhosis
with conﬁdence in clinical practice [5]. In addition, ultrasono-
graphic ﬁndings are highly operator-dependent. Conversely, TE
is a reproducible, operator-independent, and user-friendly tech-
nique that can be performed at the bedside with immediate
results [6]. Liver stiffness has been shown to correlate with hepa-
tic ﬁbrosis stages and to have excellent diagnostic accuracy for
cirrhosis [7–10]. When compared to current biomarkers and rou-
tine blood tests, TE emerges as the most accurate non-invasive
method for early detection of cirrhosis in patients with chronic
hepatitis C [11], and it is ‘‘the test to be beaten” for those devel-
oping alternative methods [12]. However, the respective values of
ultrasonography and TE for the diagnosis of cirrhosis had not yet
been directly compared.
The study by Berzigotti et al. [13] in the current issue of the
Journal of Hepatology is therefore particularly welcome. The
authors prospectively compared the diagnostic value of TE and
high-resolution ultrasound evaluation of the left lobe liver sur-
face (LLS) in 90 patients to clinical suspicion of cirrhosis and a
strong existing differential diagnosis. Cirrhosis was present in
around half the patients, as shown by histological examination
(84%) or by clinically signiﬁcant portal hypertension (hepatic
venous pressure gradient: HVPG P10 mm Hg) and compatible
clinical and laboratory data. The main ﬁnding is that LLS and TE
had similar diagnostic accuracy (respective areas under the ROC
curve: 0.88 and 0.91), although LLS was better at ruling in cirrho-
sis (positive likelihood ratio: 11.15) while TE was better at ruling
it out (negative likelihood ratio: 0.08).
LLS examination is rapid (less than 5 min) and can, like TE, be
performed at the bedside with immediate, semi-quantitative
results (smooth, irregular, or nodular liver surface). Inorder tomin-
imize observer-dependency, the authors used a novel method
based on computerized post-processing of the ultrasound images,
which allows LLS length to be determined in a standardized seg-
ment (qLLS) with excellent intra- and inter-observer reproducibil-10 vol. 52 j 786–787
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ity. Semi-quantitative assessment of LLS was superior to qLLS for
diagnosing and excluding cirrhosis but left a substantial number
of patients with indeterminate results. A signiﬁcant number of
indeterminate cases was also obtained with TE, because of the
use of two different diagnostic cut-offs (<12 kPa for the absence
and >18 kPa for the presence of cirrhosis). This use of two cut-offs
is questionable and probably unfair towards TE, although diagnos-
tic performance did not improve when a single ‘‘optimal” cut-off
(13 kPa) was used [10]. With HVPG or liver biopsy as the reference
standard, the majority of these patients with indeterminate ﬁnd-
ings proved to be free of cirrhosis but to have heterogeneous hepa-
tic status, ranging from normal to cardiac congestive liver, which
brings us to the secondpoint: are these ﬁndings applicable to other
populations? The study population consisted of a relatively small
number of highly selected patients referred to a very specialized
tertiary center. Also, HVPG measurement requires a high degree
of expertise and is not part of the routine management of patients
with suspected liver disease in most centers. Despite these limita-
tions, this study provides important data that can be translated
immediately into clinical practice. As the authors emphasize, it is
important to conduct clinical studies of patients typically encoun-
tered inday-to-day clinical care. So far,most of thedatawehaveon
non-invasive methods originate from cohorts of patients with
chronic hepatitis C, and these methods are not yet widely used in
routine practice [14].
A particularly interesting ﬁnding of this study is the fact that,
despite similar performance for diagnosing cirrhosis, the concor-
dance between the TE and LLS was only moderate. This may be
due partly to the fact that TE is applied to the right lobe and
LLS to the left lobe. However, the most likely explanation is that
TE and LLS evaluate two different, albeit complementary, charac-
teristics of cirrhosis: TE senses liver stiffness, while LLS visualizes
nodules. It is therefore not surprising that diagnostic accuracy
improves when the two methods are combined. Such a combined
approach has already been suggested to increase diagnostic accu-
racy in the absence of a ‘‘perfect” gold standard, which is the case
for liver biopsy [15]. Another advantage is the complementary
applicability of TE and LLS. Indeed, in the study by Berzigotti
et al., the applicability of LLS was much better than that of TE,
but the TE failure rate (15%) was higher than usually reported
(5%), likely owing to the inclusion of patients with ascites. How-
ever, in our experience with more than 13,000 examinations over
a 5-year period, TE is not applicable in nearly one out of ﬁve
patients [16], owing either to failure (no valid shot) (4%) or unre-
liable results (17%: valid shots <10, IQR/LSM >30% and success
rate <60%). The principal reasons are obesity (particularly large
waist circumference) and limited operator experience. Despite
these limitations, TE may still have other advantages over LLS,
such as for monitoring disease progression. Liver stiffness shows
an excellent correlation with HVPG values below 10–12 mm Hg
[17,18]. Although these ﬁndings need to be conﬁrmed in larger
independent studies, they suggest that LSM may be useful for
detecting clinically signiﬁcant portal hypertension and, thus, for
further sub-classifying compensated cirrhosis [19]. Berzigotti
et al. did not investigate the accuracy of TE for diagnosing clini-
cally signiﬁcant portal hypertension (as measured by HVPG),
but this was beyond the scope of their work. Finally, liver stiff-
ness may have prognostic value in patients with cirrhosis, sug-
gesting that TE could be used as a rapid screening tool for
allocating cirrhotic patients to speciﬁc risk categories. Longitudi-
nal studies are now needed to determine whether single or serialJournal of Hepatology 201TE examinations are predictive of decompensation, further
decompensation, or even death [20].
In conclusion, this important study suggests that cirrhosis can
be diagnosed rapidly in clinically doubtful cases, based on the
simultaneous presence of increased liver stiffness and nodules,
as detected by two simple non-invasive methods available at
the bedside. Because of its speciﬁc setting, the ﬁndings of this
study need to be conﬁrmed in larger samples and in other popu-
lations at risk of cirrhosis. The current challenge for non-invasive
methods is to detect cirrhosis in asymptomatic patients with
chronic liver diseases, in routine clinical practice.
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